Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Mediprobe Research Inc, London, ON, Canada.
Expert Opin Pharmacother. 2024 Oct;25(15):1983-1998. doi: 10.1080/14656566.2024.2416924. Epub 2024 Oct 16.
Onychomycosis is an infection of the nail bed and the nail plate. While oral antifungals are first-line for moderate-to-severe onychomycosis, topical efinaconazole 10% solution (JUBLIA®; Clenafin®) is effective and safe for mild-to-moderate severity onychomycosis. It is FDA-approved for patients aged 6 years and above.
This literature review includes pharmacokinetics, microbiology, efficacy, safety, and post-marketing surveillance. It demonstrates consistent safety and efficacy across diverse patient demographics and comorbidities, including pediatric, diabetic and the elderly populations, without systemic side effects or drug interactions.
Efinaconazole 10% solution is an important addition to the armamentarium of therapies available to treat onychomycosis. Certain subgroups respond particularly well: females versus males, children versus adults, early onset onychomycosis (<1-year disease), those with mild onychomycosis (≤25% nail involvement), absence of tinea pedis, and thin nail plates at baseline (<1 mm thickness). Efinaconazole 10% solution is effective in diabetics and has demonstrated efficacy against dermatophytomas. Efinaconazole may be a consideration when terbinafine resistance is a concern, due to its different target of action.
甲真菌病是一种累及甲床和甲板的真菌感染。虽然口服抗真菌药物是中重度甲真菌病的一线治疗药物，但 10%盐酸依氟康唑溶液（JUBLIA®；Clenafin®）对于轻度至中度甲真菌病的疗效确切且安全。该药已获得 FDA 批准，可用于 6 岁及以上的患者。
本文的文献综述包括药代动力学、微生物学、疗效、安全性和上市后监测。结果表明，在包括儿科、糖尿病和老年人群在内的不同患者人群和合并症中，该药具有一致的安全性和疗效，不会产生全身副作用或药物相互作用。
10%盐酸依氟康唑溶液是治疗甲真菌病的治疗方法之一。某些亚组患者对其反应特别好：女性优于男性，儿童优于成人，发病早的甲真菌病（<1 年），轻度甲真菌病（≤25%指甲受累），无足癣，以及基线时指甲较薄（<1mm 厚度）。在糖尿病患者中，10%盐酸依氟康唑溶液也具有疗效，并且已证实对甲真菌瘤有效。如果担心特比萘芬耐药，可以考虑使用依氟康唑，因为它的作用靶点不同。
